Trial news: The AGITG currently has seven studies open to recruitment and ten studies in follow up.
The table below details the trials that are currently accruing patients.
| Recruited | Target | |
| ACTICCA-1- Gallbladder carcinoma | 3 | 50 |
| ASCOLT — Colorectal cancer | 276 | 300 |
| CONTROL NETs — NeuroEndocrine Tumour | 69 | 72 |
| INTEGRATE II – Gastro-Oesophageal | 28 | 350 |
| NABNEC — NeuroEndocrine Tumour | 19 | 70 |
| TOP GEAR — Stomach cancer | 192 | 752 |
| DYNAMIC-III | 23 | 1,000 |
Trial Results Lay Summaries (click on the links below):Recruitment figures to end March 2018.
ALaCaRT
ATTACHE
ATTAX-3
GAP
ICECREAM
INTEGRATE
TACTIC
TOP GEAR
CO.17
EORTC 62024
Advanced GIST